

Atty's Docket: Bayer: 10197.2

IN THE CLAIMS

Amend the claims in accordance with the following:

1. (Currently amended) Preparation—A preparation which can be administered orally and contains a fixed combination of at least one locally acting analgesic with a rapid onset of action (element A) with at least one systemically acting analgesic with a sustained action (element B), wherein element A and element B are comprise different chemical analgesic compounds.
2. (Previously presented) Preparation according to claim 1, characterized in that the active substance employed as element A shows an optimal duration of action of from 0.5 to 120 minutes, and the active substance employed as element B has an action of from 15 minutes up to 24 hours.
3. (Previously presented) Preparation according to claim 1, characterized in that elements A and B are selected so that the fixed combination has a duration of action of from 2 minutes up to 12 hours.
4. (Previously presented) Process for producing a preparation according to claim 1, characterized in that the fixed combination of an active substance of element A and an active substance of element B are converted together with conventional ancillary substances and carries and, where appropriate, other compatible active substances into a suitable administration form.
5. (Previously presented) The preparation according to claim 1, which is in the form of a press-coated tablet.

Atty's Docket: Bayer: 10197.2

6. (Previously presented) The preparation according to claim 1, which is in the form of coated pastille.

7. (Previously presented) The preparation according to claim 1, which is in the form of a chewing gum.

8. (Previously presented) The preparation according to claim 1, which is in the form of a hard caramel with a liquid, semisolid or solid core.

9. (Currently amended) The preparation according to claim 1, which is in the form of a inner core tablet coated with an outer coating, wherein the outer coating comprises the at least one locally acting analgesic with a rapid onset of action (element A), the inner core tablet comprises the at least one systemically acting analgesic with a sustained action (element B), and elements A and B are different chemical analgesic compounds.

10. (Previously presented) A preparation which can be administered orally and is in the form of a inner core tablet coated with an outer coating, wherein the outer coating comprises at least one locally acting analgesic with a rapid onset of action (element A) selected from the group consisting of benzocaine, amethocaine, amylocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, chlormecaine, cyclomethycaine, isobutamben, meprylcaine, oxybuprocaine, procaine, propipocaine, proxymetacaine, tricaine, lidocaine, bupivacaine, butanilicaine, carticaine, cinchocaine, clibucaine, etidocaine, mepivacaine, oxethazaine, prilocaine, ropivacaine, ethyl p-piperidinoacetyl-aminobenzoate, tolycaine, trimecaine and vadocaine, and the inner core tablet comprises at least one systemically acting analgesic with a sustained action (element B) selected from the group consisting of aceclofenac, alclofenac, bromofenac, diclofenac,

Atty's Docket: Bayer: 10197.2

fenclofenac, acemetacin, amfenac sodium, bendazac, glucametacin, oxametacin, acetanilide, alminoprofen, ibuprofen, ketoprofen, flurbiprofen, naproxen, oxaprozin, acetyl salicylic acid, salts of acetylsalicylic acid, diflunisal, etersalate, fosfosal, salol, salsalate, salacetamide, amidopyrine, dipyrone, droxicam, Isoxicam, piroxicam, azapropazone, bumadizone calcium, oxyphenbutazone, etodolac, galfenine, sodium meclofenamate, mefenamic acid, morniflumate, idomethacin, paracetamol, paracetamol derivatives, anirolac, benzpiperylone, benzydamine hydrochloride, sodium butibufen, chlorthenoxazine, cinmetacin, clonixin, cloracetadol, difenpiramide, diproqualone, etenzamide, famprofazone, flupirtine maleate, ibuprofex, indoprofen, isamfazone, meloxicam, metiazinic acid, metifenazone, nifenazone, niflumic acid, mimesulide, pirazolac, pranoprofen, proquazone, protizinic acid and ramifenazone.

11. (Previously presented) The preparation according to claim 10, which is in the form of an inner core tablet coated with an outer coating, wherein the outer coating comprises benzocaine as the at least one locally acting analgesic with a rapid onset of action (element A), and the inner core tablet comprises acetylsalicylic acid or salt thereof as the at least one systemically acting analgesic with a sustained action (element B).

12. (Previously presented) A method of alleviating pain in a patient in need thereof comprising administering to said patient a preparation according to any one of claims 1-9.

13. (Currently amended) Preparation which can be administered orally and contains a fixed combination of at least one locally acting analgesic with a rapid onset of action (element A) with at least one systemically acting analgesic with a sustained action (element B), wherein element A and element B are different chemical analgesic

Atty's Docket: Bayer: 10197.2

compounds, and the preparation is formulated such that element A is released from the preparation before element B upon oral administration.

14. (Previously presented) A method of alleviating pain in a patient in need thereof comprising administering to said patient a preparation according to claim 10 or 11.

15. (Previously presented) A method of alleviating pain in a patient in need thereof comprising administering to said patient a preparation according to claim 13.

16. (Currently amended) An analgesic preparation comprising,  
a) element A, which further comprises at least one locally acting analgesic having a rapid onset of action,  
b) element B, which further comprises a core tablet having at least one systemically acting analgesic having sustained action,

and wherein element A is a coating that encloses at least a portion of said core tablet's surface area and wherein the analgesic in element A is different from the one analgesic in element B .

17. (Previously presented) The analgesic preparation of claim 16, wherein element A entirely encloses element B.

18. (Previously presented) The analgesic preparation of claim 16, wherein element A encloses less than 100% of element B's surface area.

Atty's Docket: Bayer: 10197.2

19. (Previously presented) The analgesic preparation of claim 16, wherein the at least one locally acting analgesic is selected from the group consisting of benzocaine, amethocaine, amylocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, chlormecaine, cyclomethycaine, isobutamben, meprylcaine, oxybuprocaine, procaine, propipocaïne, proxymetacaine, tricaine, lidocaine, bupivacaine, butanilicaine, carticaine, cinchocaine, clibucaïne, etidocaine, mepivacaïne, oxethazaine, prilocaine, ropivacaïne, ethyl p-piperidinoacetyl-aminobenzoate, tolycaine, trimetacaine and vadocaine.

20. (Previously presented) The analgesic preparation of claim 16, wherein the at least one systemically acting analgesic having sustained action, is selected from the group consisting of aceclofenac, alclofenac, bromofenac, diclofenac, fenclofenac, acemetacin, amfenac sodium, bendazac, glucametacin, oxametacin, acetanilide, alminoprofen, ibuprofen, ketoprofen, flurbiprofen, naproxen, oxaprozin, acetyl salicylic acid, salts of acetyl salicylic acid, diflunisal, etersalate, fosfosal, salol, salsalate, salacetamide, amidopyrine, dipyrone, droxicam, isoxicam, piroxicam, azapropazone, bumadizone calcium, oxyphenbutazone, etodolac, galfenine, sodium meclofenamate, mefenamic acid, morniflumate, idomethacin, paracetamol, paracetamol derivatives, anirolac, benzpiperylone, benzydamine hydrochloride, sodium butibufen, chlorthenoxazine, cinmetacin, clonixin, cloracetadol, difenpiramide, diproqualone, etenzamide, famprofazone, flupirtine maleate, ibuprofam, indoprofen, isamfazone, meloxicam, metiazinic acid, metifenazoné, nifenazone, niflumic acid, mimesulide, pirazolac, pranoprofen, proquazone, protizinic acid and ramifenazone.

Atty's Docket: Bayer: 10197.2

21. (Currently amended) An analgesic preparation comprising an element A and an element B, wherein,

a) element A further comprises at least one locally acting analgesic having a rapid onset of action, said at least one locally acting analgesic being selected from the group consisting of benzocaine, amethocaine, amylocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, chlormecaine, cyclomethcaine, isobutamben, meprylcaine, oxybuprocaine, procaine, propipocaine, proxymetacaine, tricaine, lidocaine, bupivacaine, butanilicaine, carticaine, cinchocaine, clibucaine, etidocaine, mepivacaine, oxethazaine, prilocaine, ropivacaine, ethyl p-piperidinoacetyl-aminobenzoate, tolycaine, trimecaine and vadocaine; and

b) element B comprises at least one systemically acting analgesic having sustained action,

and wherein the locally acting analgesic having a rapid onset of action that comprises element A is distinct from the analgesic in element B.

22. (Currently amended) An analgesic preparation comprising an element A and an element B, wherein,

a) element A further comprises at least one locally acting analgesic having a rapid onset of action; and

b) element B further comprises at least one systemically acting analgesic having sustained action, wherein said at least one systemically acting analgesic is selected from the group consisting of aceclofenac, alclofenac, bromofenac, diclofenac, fenclofenac,

Atty's Docket: Bayer: 10197.2

acetmetacin, amfenac sodium, bendazac, glucametacin, oxametacin, acetanilide, alminoprofen, ibuprofen, ketoprofen, flurbiprofen, naproxen, oxaprozin, acetyl salicylic acid, salts of acetylsalicylic acid, diflunisal, etersalate, fosfosal, salol, salsalate, salacetamide, amidopyrine, dipyrone, droxicam, isoxicam, piroxicam, azapropazone, bumadizone calcium, oxyphenbutazone, etodolac, galferine, sodium meclofenamate, mefenamic acid, morniflumate, idomethacin, paracetamol, paracetamol derivatives, anirolac, benzpiperylone, benzydamine hydrochloride, sodium butibufen, chlorthenoxazine, cinmetacin, clonixin, cloracetadol, difenpiramide, diproqualone, etenzamide, famprofazone, flupirtine maleate, ibuproxam, indoprofen, isamfazole, meloxicam, metiazinic acid, metifenazole, nifenazole, niflumic acid, mimesulide, pirazolac, pranoprofen, proquazone, protizinic acid and ramifenazole,

and wherein the locally acting analgesic having a rapid onset of action that comprises element A is distinct from the analgesic in element B.

23. (Currently amended) An analgesic preparation comprising,

- a) element A, which further comprises at least one locally acting analgesic having a rapid onset of action,
- b) element B, which further comprises at least one systemically acting analgesic having sustained action,

and wherein the at least one analgesic comprising both element A and element B are different analgesic compounds, and each is independently provided in said preparation in a manner that

Atty's Docket: Bayer: 10197.2

resist commingling of said element A and element B until administration of said preparation to a subject.

24. (Previously presented) The analgesic preparation of claim 23, wherein the preparation is a chewable gum or chewable candy that further comprises at least one distinct region having element A, and at least one distinct region having element B, and wherein said regions do not commingle prior to administering said preparation to a subject.

25. (Previously presented) The analgesic preparation according to claim 23, wherein the preparation is a solid form of candy, having a liquid center.

26. (Previously presented) The analgesic preparation of claim 24, wherein the regions are juxtaposed in a pattern of bar-shaped stripes.

27. (Previously presented) The analgesic preparation of claim 24, wherein the regions comprising each of said element A or B, further comprise layers, stacked one on top of the other.

28. (Currently amended) A preparation which that can be administered orally and comprises a fixed combination of at least one locally acting ester-type anesthetic having a rapid onset of action (element A), and further comprising at least one systemically acting analgesic with a sustained action (element B), wherein,

(i) element A and element B are comprise different chemical analgesic compounds, and

(ii) element A comprises an outer coating that envelopes a core tablet comprising element B.